title: Metastatic hormone-sensitve prostate cancer (mHSPC) biopsy sample 22 scRNAseq
design: To understand the evolution of the mechanisms underlying myeloid-mediated immunotherapy resistance and to identify targets for enhancing therapeutic efficacy in prostate cancer, we performed single-cell profiling of patient biopsies from cases of localized, metastatic hormone-sensitive prostate cancer, or mCRPC. We then reverse translated these findings in a syngeneic mouse model (MyC-CaP) of HSPC and CRPC, conducting multi-omic single-cell assessment and studies to assess tumor efficacy and gain mechanistic insights.